Liquidia Says US FDA Grants Fast Track Designation to Yutrepia in Systemic Sclerosis

08:23 AM EDT, 09/03/2026 (MT Newswires) -- Liquidia (LQDA) said Thursday the US Food and Drug Administration has granted fast track designation to Yutrepia inhalation powder to treat Raynaud's phenomenon associated with systemic sclerosis. The potential use is currently under clinical development, and the treatment's safety and efficacy have not been evaluated yet, the company said. Liquidia said it plans to initiate a phase 2a dose-finding study of Yutrepia in October, with primary completion targeted for February 2027. The study also looks at whether the treatment makes Raynaud's phenomenon attacks happen less often, feel less painful, and cause fewer problems in daily life. FDA's fast track designation is intended to facilitate the development and expedite the review of drugs intended to treat serious conditions and address unmet medical need, Liquidia said.